1 month ago
2
Aurobindo Pharma’s Board has approved the generic drugmaker’s connection to buyback much than 54.23 lakh equity shares astatine ₹1,475 each.
The buyback terms is astatine a premium of much than 10% from the erstwhile trading day’s (April2) closing terms of ₹1,335.95. Aurobindo Pharma shares had touched a 52-week precocious astatine ₹1,359 each connected April 1.
The buyback, for an aggregate magnitude of ₹800 crore, is projected to beryllium made from each shareholders / beneficial owners, including promoters and members of the promoter group, who clasp equity shares arsenic of the grounds date, connected a proportionate ground done the “tender offer” route, the institution said pursuing the Board determination connected Monday (April 6, 2026).
April 17, 2026 has been acceptable arsenic the grounds day for the intent of determining the entitlement and the names of equity shareholders who would beryllium eligible to enactment successful the buyback, the institution said.
This is the 2nd buyback by the institution successful little than 2 years. Previously, successful July 2024 it had announced and August of the aforesaid twelvemonth completed a ₹750 crore buyback of much than 51.36 lakh shares astatine a terms of ₹1,460 each.
Under the latest buyback proposal, approved connected Monday, the fig of shares mentioned correspond to 0.93% of the full fig of equity shares successful the paid-up equity stock capital, the institution said. Promoters and promoter radical holding, successful Aurobindo Pharma, is 51.82%, portion the nationalist holding is 7.93%.
